Second Line Chemotherapy FOLFIRINOX in Irresectable Cholangiocarcinoma
Status:
Completed
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
Cholangiocarcinoma, is a malignant gastrointestinal tumor of low incidence with a poor
prognosis. Chemotherapy is the most common treatment for advanced disease. On the basis of a
phase III clinical study, cisplatin plus gemcitabine is considered standard first-line
treatment in advanced cholangiocarcinoma patients, but there is no established second line
therapy.
Since fluorouracil and leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX)
appears to be safe and demonstrated efficacy in clinical studies of advanced pancreatic
cancer, colorectal cancer and a phase I study in cholangiocarcinoma, this combination could
be an effective second-line treatment for patients with advanced cholangiocarcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)